Twist Bioscience Corp. (TWST)

Over the past six months, Twist Bioscience's stock price has experienced notable movements, with a 52-week low of $23.30 on November 14, 2025. As of May 1, 2026, the share price was $60.40. Recent events impacting the stock include the Q2 2026 earnings announcement, the launch of "Complex Genes" as an early access offering, an AI-focused partnership with Amazon Web Services, and participation in several healthcare conferences in March 2026.

The gene synthesis business is characterized by its on-demand nature, requiring manufacturing operations to run 24/7/365, suggesting consistent demand rather than pronounced seasonality. The company's platform and scalable production process are designed to address the growing and continuous demand for synthetic genes. Growth in the NGS segment has been noted from increased clinical diagnostic demand.

Twist Bioscience Corp. is a biotechnology company specializing in synthetic DNA production and genomic solutions, operating within the Healthcare sector. It leverages a silicon-based DNA synthesis platform to manufacture high-quality synthetic DNA at scale. Its major product categories include synthetic DNA products, biopharma solutions, data storage solutions, and industrial and agricultural applications. The company has expanded its clonal genes portfolio with an early access launch of "Complex Genes" for long and complex sequences.

Twist Bioscience's operations extend globally, with a presence across the Americas, EMEA, and APAC. The Americas currently represent its largest market.

Twist Bioscience maintains a reputation as a leading and innovative company in synthetic biology and genomics. The company is recognized for its disruptive DNA synthesis platform and its ability to produce high-quality synthetic DNA at scale. The expansion of its product offerings and strategic partnerships contribute positively to its image as a forward-thinking and expanding entity. There were no specific negative events significantly impacting its brand reputation reported in the past year.

Twist Bioscience's ownership structure is predominantly institutional, with key investors including ARK Investment Management LLC, Vanguard Group Inc., and BlackRock, Inc. Individual investors and public companies also hold a notable portion of shares, with Ever Alpha Fund LP being a significant individual shareholder. Founders and executives, including CEO Emily Leproust, retain a smaller but notable stake.